Affinity-enrichment of thyrotropin receptor autoantibodies from Graves' patients and normal individuals provides insight into their properties and possible origin from natural antibodies

被引:39
作者
Latrofa, F
Chazenbalk, GD
Pichurin, P
Chen, CR
McLachlan, SM
Rapoport, B
机构
[1] Cedars Sinai Med Ctr, Autoimmune Dis Unit, Los Angeles, CA 90048 USA
[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90048 USA
关键词
D O I
10.1210/jc.2003-032068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We used purified recombinant TSH receptor (TSHR) antigen prepared in mammalian cells to affinity-enrich TSHR autoantibodies from Graves' patients' IgG. Autoantibody enrichment, assayed by TSH binding inhibitory activity, was 20- to 1000-fold. Thyroid-stimulating antibody activity enrichment, although more difficult to quantitate, was comparable. TSHR-autoantibody approximate affinities for the holoreceptor assessed indirectly by TSH binding inhibition were 4-27 x 10(-9) M, an underestimate because 100% TSHR autoantibody purity was not attained. Consistent with previous data for serum, highly enriched TSHR autoantibodies in three of four patients showed lambda light chain bias. However, in contrast to expectations, antigen-enriched IgG was skewed primarily toward IgG2 and IgG3, subclasses associated with polysaccharides and microorganisms, respectively. Subclass depletion studies on antigen-enriched IgG indicated that TSHR autoantibodies were predominantly IgG1 and, surprisingly, IgG4. As controls, we affinity-enriched pooled IgG from normal individuals on TSHR antigen. This enriched IgG had detectable TSH binding inhibitory activity, although with lower specific activity than, and lacking the thyroid stimulatory activity of, Graves' IgG. Moreover, these natural IgG class autoantibodies largely recognized the same conformational variation in the TSHR N-terminal region as disease-associated TSHR autoantibodies. These studies suggest that TSHR autoantibodies may arise from natural autoantibodies, possibly by class switching from cross-reacting antibodies to microorganisms.
引用
收藏
页码:4734 / 4745
页数:12
相关论文
共 42 条
[1]   A monoclonal thyroid-stimulating antibody [J].
Ando, T ;
Latif, R ;
Pritsker, A ;
Moran, T ;
Nagayama, Y ;
Davies, TF .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (11) :1667-1674
[2]   Autoantibodies interacting with purified native thyrotropin receptor [J].
Atger, M ;
Misrahi, M ;
Young, J ;
Jolivet, A ;
Orgiazzi, J ;
Schaison, G ;
Milgrom, E .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 265 (03) :1022-1031
[3]   AUTOANTIGENIC DETERMINANTS ON HUMAN THYROGLOBULIN .2. DETERMINANTS RECOGNIZED BY AUTOANTIBODIES FROM PATIENTS WITH CHRONIC AUTOIMMUNE-THYROIDITIS COMPARED TO AUTOANTIBODIES FROM HEALTHY-SUBJECTS [J].
BRESLER, HS ;
BUREK, CL ;
HOFFMAN, WH ;
ROSE, NR .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1990, 54 (01) :76-86
[4]   PARTIAL-PURIFICATION AND CHARACTERIZATION OF THYROTROPIN BINDING INHIBITORY IMMUNOGLOBULINS FROM NORMAL HUMAN-PLASMA [J].
BROWN, RS ;
KERTILES, LP ;
REICHLIN, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 56 (01) :156-163
[5]   Evidence for negative cooperativity among human thyrotropin receptors overexpressed in mammalian cells [J].
Chazenbalk, GD ;
Kakinuma, A ;
Jaume, JC ;
McLachlan, SM ;
Rapoport, B .
ENDOCRINOLOGY, 1996, 137 (11) :4586-4591
[6]   Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera [J].
Chazenbalk, GD ;
Jaume, JC ;
McLachlan, SM ;
Rapoport, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (30) :18959-18965
[7]   A mouse monoclonal antibody to a thyrotropin receptor ectodomain variant provides insight into the exquisite antigenic conformational requirement, epitopes and in vivo concentration of human autoantibodies [J].
Chazenbalk, GD ;
Wang, Y ;
Guo, J ;
Hutchison, JS ;
Segal, D ;
Jaume, JC ;
McLachlan, SM ;
Rapoport, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) :702-710
[8]   Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor [J].
Chazenbalk, GD ;
Pichurin, P ;
Chen, CR ;
Latrofa, F ;
Johnstone, AP ;
McLachlan, SM ;
Rapoport, B .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (02) :209-217
[9]   A prion-like shift between two conformational forms of a recombinant thyrotropin receptor A-subunit module: Purification and stabilization using chemical chaperones of the form reactive with Graves' autoantibodies [J].
Chazenbalk, GD ;
McLachlan, SM ;
Pichurin, P ;
Yan, XM ;
Rapoport, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) :1287-1293
[10]   A full biological response to autoantibodies in Graves' disease requires a disulfide-bonded loop in the thyrotropin receptor N terminus homologous to a laminin epidermal growth factor-like domain [J].
Chen, CR ;
Tanaka, K ;
Chazenbalk, GD ;
McLachlan, SM ;
Rapoport, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (18) :14767-14772